The promised national breast-screening programme seems to be one step closer with a team of EU experts on breast screening expected to carry out a pre-implementation evaluation visit next month.
According to Nadine Delicata, who was appointed project leader for the national screening programme, the next step in the process to set up the screening programme, which was announced in the last budget speech, is a pre-implementation evaluation visit by an EU team of experts on breast screening. This visit is planned for late November.
The screening programme will target women aged between 50 and 60 – the age group which statistically is at the highest risk of breast cancer.
This is welcome news especially since an awareness campaign was held this month by the Breast Care Support Group and in the light of the government’s recent announcement that the drug Herceptin will be available in the health service for the treatment of breast cancer.
About 40 women will benefit from free Herceptin every year. The medicine is administered to women at level three of the disease who have already been operated on. It was calculated the decision would cost e32,000 for each patient each year, or about e1.3 million annually.
Dr Delicata was appointed project leader of the national screening programme just over a year ago. She said the supporting systems necessary for a well-organised screening programme is being put in place and most of the preparatory work has been completed.
“Since we did not have any established mechanisms in place for organised health screening surveillance in Malta we had to start from scratch. Our existing systems are run along ‘opportunistic’ lines with screening undertaken at the discretion of the patient and their personal physician,” Dr Delicata said.
The screening service will be subject to guidelines on Quality Assurance (QA) standards from Europe. As a result, once the screening service is established, its performance will be under constant review both locally and at EU level.
The EU guidelines are revised on a regular basis and the project team will act as part of the interface between the EU and the professionals providing the service.
The programme will be required to regularly submit activity data and statistics to EU and other international bodies.
Perhaps from the public health perspective establishing the cost-effectiveness of breast screening interventions is a critical exercise. The team has meticulously researched this and carefully evaluated the cost-benefits of investing resources into this important aspect of health care.